What we have learned from the Optic Neuritis Treatment Trial

Ophthalmology. 1995 Oct;102(10):1504-8. doi: 10.1016/s0161-6420(95)30839-1.
No abstract available

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute Disease
  • Administration, Oral
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use*
  • Brain / pathology
  • Female
  • Humans
  • Injections, Intravenous
  • Magnetic Resonance Imaging
  • Male
  • Methylprednisolone Hemisuccinate / administration & dosage
  • Methylprednisolone Hemisuccinate / adverse effects
  • Methylprednisolone Hemisuccinate / therapeutic use*
  • Middle Aged
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / etiology
  • Multiple Sclerosis / prevention & control
  • Optic Neuritis / drug therapy*
  • Optic Neuritis / physiopathology
  • Prednisolone / administration & dosage
  • Prednisolone / adverse effects
  • Prednisolone / therapeutic use*
  • Treatment Outcome
  • Visual Acuity / physiology

Substances

  • Anti-Inflammatory Agents
  • Methylprednisolone Hemisuccinate
  • Prednisolone